JP2014511348A5 - - Google Patents

Download PDF

Info

Publication number
JP2014511348A5
JP2014511348A5 JP2013549892A JP2013549892A JP2014511348A5 JP 2014511348 A5 JP2014511348 A5 JP 2014511348A5 JP 2013549892 A JP2013549892 A JP 2013549892A JP 2013549892 A JP2013549892 A JP 2013549892A JP 2014511348 A5 JP2014511348 A5 JP 2014511348A5
Authority
JP
Japan
Prior art keywords
agent
cancer
antibody
group
il1rap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013549892A
Other languages
English (en)
Japanese (ja)
Other versions
JP5940093B2 (ja
JP2014511348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2012/050120 external-priority patent/WO2012098407A1/en
Publication of JP2014511348A publication Critical patent/JP2014511348A/ja
Publication of JP2014511348A5 publication Critical patent/JP2014511348A5/ja
Application granted granted Critical
Publication of JP5940093B2 publication Critical patent/JP5940093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013549892A 2011-01-19 2012-01-19 抗il−1rap抗体及びヒトを処置するためのそれらの使用 Active JP5940093B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434040P 2011-01-19 2011-01-19
US61/434,040 2011-01-19
PCT/GB2012/050120 WO2012098407A1 (en) 2011-01-19 2012-01-19 Anti - il1rap antibodies and their use for treating human

Publications (3)

Publication Number Publication Date
JP2014511348A JP2014511348A (ja) 2014-05-15
JP2014511348A5 true JP2014511348A5 (enExample) 2015-03-12
JP5940093B2 JP5940093B2 (ja) 2016-06-29

Family

ID=45755402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549892A Active JP5940093B2 (ja) 2011-01-19 2012-01-19 抗il−1rap抗体及びヒトを処置するためのそれらの使用

Country Status (14)

Country Link
US (4) US9403906B2 (enExample)
EP (3) EP2665749B1 (enExample)
JP (1) JP5940093B2 (enExample)
KR (1) KR101989134B1 (enExample)
CN (2) CN107929730A (enExample)
AU (1) AU2012208379B2 (enExample)
BR (1) BR112013018399B1 (enExample)
CA (1) CA2824719C (enExample)
DK (2) DK2665749T3 (enExample)
ES (2) ES2714716T3 (enExample)
MX (1) MX354450B (enExample)
PL (2) PL2665749T3 (enExample)
RU (1) RU2597831C2 (enExample)
WO (1) WO2012098407A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110044894A1 (en) 2008-03-26 2011-02-24 Cellerant Therapeutics, Inc. Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
RU2597831C2 (ru) 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
WO2013023015A2 (en) 2011-08-11 2013-02-14 Albert Einstein College Of Medicine Of Yeshiva University Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
CN113072644A (zh) 2013-12-17 2021-07-06 埃姆医疗有限公司 抵抗骨髓增生障碍或淋巴组织增生障碍的手段和方法
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2016085832A1 (en) * 2014-11-24 2016-06-02 Albert Einstein College Of Medicine, Inc. Peptides for blocking il1rap protein-protein interaction and uses thereof for treatment of disease
CA2990305A1 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
MA43164A (fr) * 2015-11-02 2018-09-12 Janssen Pharmaceutica Nv Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US11359025B2 (en) 2016-10-16 2022-06-14 Cantargia Ab Anti-IL1-RAP antibodies
FI3548515T3 (fi) 2016-12-01 2026-03-04 Regeneron Pharma Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen
US10067409B2 (en) 2017-02-02 2018-09-04 James Harrison Elias Camera supporting base
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
HUE067040T2 (hu) 2017-05-16 2024-09-28 Byondis Bv Anti-SIRPalfa antitestek
USD951260S1 (en) 2017-05-19 2022-05-10 James Harrison Elias Electronic device mount
US11162632B2 (en) 2017-06-02 2021-11-02 James Harrison Elias Tripod stabilizing base
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン, インコーポレイテッド 抗-il1rap抗体および抗体薬物コンジュゲート
JP2020533960A (ja) 2017-08-01 2020-11-26 シティ・オブ・ホープCity of Hope 抗il1rap抗体
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
CN112638946A (zh) 2018-08-16 2021-04-09 坎塔吉亚有限责任公司 抗il1rap抗体组合物
TW202021618A (zh) 2018-08-17 2020-06-16 美商23與我有限公司 抗il1rap抗體及其使用方法
CA3118966A1 (en) 2018-11-15 2020-05-22 Byondis B.V. Humanized anti-sirpa antibodies
USD896878S1 (en) 2018-11-29 2020-09-22 James Harrison Elias Tripod mount
USD888139S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD900201S1 (en) 2018-11-29 2020-10-27 James Harrison Elias Tripod mount
USD888141S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD888142S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD888140S1 (en) 2018-11-29 2020-06-23 James Harrison Elias Tripod mount
USD888815S1 (en) 2018-11-29 2020-06-30 James Harrison Elias Tripod mount
USD897414S1 (en) 2018-11-29 2020-09-29 James Harrison Elias Tripod mount
USD888817S1 (en) 2018-11-30 2020-06-30 James Harrison Elias Tripod mount
USD896880S1 (en) 2018-11-30 2020-09-22 James Harrison Elias Tripod mount
USD896879S1 (en) 2018-11-30 2020-09-22 James Harrison Elias Tripod mount
USD888816S1 (en) 2018-11-30 2020-06-30 James Harrison Elias Tripod mount
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療
MA56397A (fr) 2019-06-26 2022-05-04 Glaxosmithkline Ip Dev Ltd Protéines de liaison à l'il1rap
EP4013794A4 (en) * 2019-08-12 2023-11-22 City of Hope ANTI-IL1RAP ANTIBODIES
CN115942975A (zh) * 2020-04-10 2023-04-07 西雅图儿童医院(Dba西雅图儿童研究所) 白细胞介素-1受体辅助蛋白的特异性结合域和嵌合抗原受体
JP2023541627A (ja) 2020-09-14 2023-10-03 イシュノス サイエンシズ ソシエテ アノニム Il1rapに結合する抗体及びその使用
MX2023007611A (es) 2020-12-23 2023-07-12 Cantargia Ab Anticuerpo anti-il1rap.
CN114736885A (zh) * 2022-05-27 2022-07-12 四川大学华西医院 一种携带bcr-abl1基因激酶区双位点突变的细胞株及其构建方法
CA3268115A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized Anti-IL-1R3 Antibodies and Methods of Use
AU2024270136A1 (en) 2023-05-05 2025-11-20 Otsuka Pharmaceutical Co., Ltd. Anti-il1rap antibodies
WO2025027529A1 (en) * 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
GB202402046D0 (en) * 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
WO2025201513A1 (zh) * 2024-03-29 2025-10-02 珠海丹序生物制药有限公司 抗il1rap抗体及其用途
WO2025209480A1 (zh) * 2024-04-02 2025-10-09 福佑泰生物制药公司 抗il1rap抗体以及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
CN1169754A (zh) * 1995-01-23 1998-01-07 霍夫曼-拉罗奇有限公司 人白介素-1受体辅助蛋白
PE64396A1 (es) * 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6280955B1 (en) 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
US20030215453A1 (en) 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
AU2002253842A1 (en) 2000-10-31 2002-08-28 Immunex Corporation Il-1 receptor accessory protein
AU2002324625B2 (en) 2001-08-07 2008-05-08 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
RU2007130722A (ru) 2005-02-16 2009-03-27 Вайет (Us) Способы и устройства для диагностики, прогнозирования и выбора лечения лейкоза
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
EP2500352A1 (en) * 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007112097A2 (en) 2006-03-24 2007-10-04 Children's Medical Center Corporation Novel signature self renewal gene expression programs
JP2010507366A (ja) 2006-10-19 2010-03-11 メルク アンド カンパニー インコーポレイテッド インターロイキン−13受容体α1の抗体アンタゴニスト
PL4160212T3 (pl) 2008-01-15 2024-08-12 The Board Of Trustees Of The Leland Stanford Junior University Markery komórek macierzystych ostrej białaczki szpikowej
US20110044894A1 (en) 2008-03-26 2011-02-24 Cellerant Therapeutics, Inc. Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
RU2597831C2 (ru) 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) * 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
CA2990305A1 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
MA43164A (fr) 2015-11-02 2018-09-12 Janssen Pharmaceutica Nv Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
US11359025B2 (en) 2016-10-16 2022-06-14 Cantargia Ab Anti-IL1-RAP antibodies
WO2018071910A2 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies

Similar Documents

Publication Publication Date Title
JP2014511348A5 (enExample)
RU2013138439A (ru) Анти-il1rap антитела и их применение при лечении людей
ES2686692T3 (es) Anticuerpo monoclonal anti CD146
ES2885686T3 (es) Conjugados anticuerpo-fármaco hidrófilos
JP2025013502A (ja) 悪性脳腫瘍における標的化粒子の浸透、分布および応答のための組成物及び方法
ES2706428T3 (es) Inmunoconjugado de IL-12
ES2341625T3 (es) Anticuerpos monoclonales anti-cd71 y sus utilizaciones para el tratamiento de las celulas tumorales malignas.
ES2289174T3 (es) Anticuerpos contra el antigeno muc-18.
Schäfer et al. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma
ES2773504T3 (es) Nuevo polipéptido que tiene afinidad por PD-L1
Quiles et al. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy
JP2005516965A (ja) 抗muc18抗体を使用する方法
JP6738909B2 (ja) 血液悪性疾患を処置するための低用量抗体に基づく方法
US10519246B2 (en) Anti-fibroblast activation protein (FAP) antibodies for treatment and diagnosis
Goldenberg et al. Using antibodies to target cancer therapeutics
CA3205707A1 (en) Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
RU2019111303A (ru) Антитела против edb и конъюгаты антитело-лекарственное средство
JP2024528496A (ja) ウロキナーゼ型プラスミノーゲン活性化因子受容体関連タンパク質(uparap)を標的とするヒト化抗体を含む、抗体薬物複合体
CA3196402A1 (en) Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
JP2025506485A (ja) Peg化抗体ヒドロキシル含有薬物複合体
Ghani et al. Antibody fragment and targeted colorectal cancer therapy: a global systematic review
Liu et al. Epidermal growth factor receptor–targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab
US20200197547A1 (en) Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers
US20250281654A1 (en) Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents
Shao et al. Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C